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Abstract
Introduction Additional biomarkers in sepsis are needed to tackle the challenges of determining
prognosis and optimizing selection of high-risk patients for application of therapy. In the present study,
conducted in a cohort of medical intensive care unit patients, our aim was to compare the prognostic
value of mid-regional pro-atrial natriuretic peptide (ANP) levels with those of other biomarkers and
physiological scores.
Methods Blood samples obtained in a prospective observational study conducted in 101 consecutive
critically ill patients admitted to the intensive care unit were analyzed. The prognostic value of pro-ANP
levels was compared with that of the Acute Physiology and Chronic Health Evaluation (APACHE) II
score and with those of various biomarkers (i.e. C-reactive protein, IL-6 and procalcitonin). Mid-regional
pro-ANP was detected in EDTA plasma from all patients using a new sandwich immunoassay.
Results On admission, 53 patients had sepsis, severe sepsis, or septic shock, and 68 had systemic
inflammatory response syndrome. The median pro-ANP value in the survivors was 194 pmol/l (range
20–2000 pmol/l), which was significantly lower than in the nonsurvivors (median 853.0 pmol/l, range
100–2000 pmol/l; P < 0.001). On the day of admission, pro-ANP levels, but not levels of other
biomarkers, were significantly higher in surviving than in nonsurviving sepsis patients (P = 0.001). In a
receiver operating characteristic curve analysis for the survival of patients with sepsis, the area under
the curve (AUC) for pro-ANP was 0.88, which was significantly greater than the AUCs for procalcitonin
and C-reactive protein, and similar to the AUC for the APACHE II score.
Conclusion Pro-ANP appears to be a valuable tool for individual risk assessment in sepsis patients and
for stratification of high-risk patients in future intervention trials. Further studies are needed to validate
our results.
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Introduction
Affecting about 700,000 people annually, sepsis accounts for
210,000 deaths each year in the USA, and both of these fig-
ures are likely to increase [1,2]. Sepsis is not an homogenous
disease; rather, it is a complex clinical syndrome with distinct
immunological features [3,4]. The ambiguity of clinical findings
and unclear risk stratification in sepsis have been major prob-
lems in sepsis intervention trials [5]. The effectiveness of anti-
inflammatory treatment correlates with risk for death and
severity of disease [6]. Thus, the prognosis of a septic patient
may contribute significantly to the success of any intervention
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[5]. Within this context, there is need for biomarkers to tackle
the challenges of sepsis monitoring and treatment [7].
Members of the natriuretic peptide family are established
markers of congestive heart failure [8-10]. Defending against
hypertension and salt and water retention, they antagonize the
renin–angiotensin–aldosterone system, including effects on
renal tubule sodium reabsorption, vascular tone and cell
growth. Atrial natriuretic peptide (ANP) is predominantly pro-
duced in the atrium of the heart and comprises 98% of natriu-
retic peptides in the circulation [11]. Recently, both ANP and
pro-ANP have attracted interest as new markers in the field of
sepsis [12-16]. Mature ANP is derived from carboxyl-terminal
amino acids 99–126 of the prohormone (pro-ANP), which is
126 amino acids in length [11]. The amino-terminal portion of
pro-ANP (termed NT-pro-ANP, or pro-ANP1–98) is secreted at
the same molar ratio as ANP. Because it has a much longer
half-life than has mature ANP, it has been suggested that pro-
ANP1–98 is a more reliable analyte [17]. However, results from
various competitive immunoassays and high-performance liq-
uid chromatography analyses indicate that pro-ANP1–98 may
be subject to further fragmentation [18,19]. Consequently,
sandwich immunoassays for pro-ANP1–98  might underesti-
mate actual levels of pro-ANP, and immunoassays for meas-
urement of mid-regional pro-ANP may have an advantage [20].
In the present study we aimed to evaluate the prognostic value
of mid-regional pro-ANP levels in a well defined cohort of med-
ical intensive care unit (ICU) patients as compared with those
of other biomarkers (i.e. IL-6, C-reactive protein [CRP] and
procalcitonin [PCT]) and a physiological score (Acute Physiol-
ogy and Chronic Health Evaluation [APACHE] II).
Methods
Patients
In the present study we evaluated plasma samples from a
cohort of 101 consecutive critically ill patients admitted to the
medical ICU of the University Hospital of Basel, Switzerland.
The primary end-point of this study was the prognostic value
of endocrine dysfunction in critically ill patients ('PEDCRIP'
study). The characteristics of the study population, study
design, diagnostic criteria and levels of various markers of
inflammation and infection were reported in detail elsewhere
[21-24]. Briefly, over a 9-month period 101 consecutive
patients, including neutropenic and immunosuppressed
patients, admitted to the medical ICU were included. Patients
were followed until hospital discharge or death.
Data were collected on admission (i.e. during the first 24
hours), on day 2, and on the day of discharge from the ICU or
on the day of death. At these time points (a total of 276 plasma
samples), patients were either very sick or in a stable condition
and ready for discharge to a medical ward, respectively. In
patients who died within 24 hours after admission, only data
from admission were collected (n = 5). Vital signs, clinical sta-
tus and severity of disease parameters (APACHE II score)
were assessed daily. The APACHE II score was calculated by
means of maximal daily deviations of 12 physiological variables
from normal plus correction for age and various chronic ill-
nesses. A pulmonary artery catheter was not routinely
inserted. When feasible, consent was obtained from con-
scious patients before enrolment; otherwise, consent was
obtained from the next of kin. The study protocol had been
granted approval by the hospital institute's ethical review
board.
Patients were classified at the time of blood collection into
those with systemic inflammatory response syndrome (SIRS),
sepsis, severe sepsis and septic shock, which were defined
according to international criteria [25,26]. Infection was diag-
nosed according to standardized criteria or, in case of uncer-
tainty, by an infectious disease specialist. This was done
retrospectively on the basis of review of complete patient
charts, results of microbiological cultures, chest radiographs
and, when available, autopsy reports. An isolated micro-organ-
ism was considered to be pathogenic if it was identified within
a 24-hour period before or after the onset of the systemic
response. Colonization with bacteria (e.g. in a patient with a
bladder catheter but without leucocyturia) or positive blood
cultures at autopsy were disregarded. Microbiological tests
were requested and antibiotic therapy prescribed by physi-
cians on duty according to the usual practice, without interfer-
ence from the research team.
Although optimal fluid resuscitation was done in the initial
treatment phase in all patients, 31% of septic patients needed
additional treatment with intravenous noradrenaline (norepine-
phrine). The mean dose of noradrenaline on admission was
8.7 ± 12.1 µg/min, on day 2 it was 10.1 ± 10.9 µg/min and on
the day of discharge/death it was 47.2 ± 35.2 µg/min (P <
0.001). Nonsurvivors from severe sepsis and septic shock
needed higher doses of noradrenaline than did survivors (5.7
± 7.8 µg/min versus 30.5 ± 28.1 µg/min; P < 0.001). Overall,
23 of the 101 patients died (22.8%). The majority of patients
who died suffered from multiple organ failure (56.5%), defined
as failure of two or more vital organs.
Assays
Results of the routine blood analyses (i.e. complete blood
count, serum chemistry including CRP, blood gas analyses)
were known and recorded. Blood was obtained from an ind-
welling arterial or venous catheter. Plasma was separated from
the blood samples at the time of blood draw and frozen at -
70°C until assayed. Measurement was done in a blinded man-
ner as a batch analysis.
Mid-regional pro-ANP (epitopes covering amino acids 53–90)
was detected in EDTA plasma from all patients with a new
sandwich immunoassay (BRAHMS Seristra® LIA; BRAHMS
AG, Hennigsdorf/Berlin, Germany), as described in detailAvailable online http://ccforum.com/content/9/1/R37
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elsewhere [20]. As a modification to the published assay, the
calibration was changed from a synthetic peptide to pro-ANP
in human serum. This modification to the initial description
increased the precision and dynamic (i.e. signal to noise ratio)
of the assay, and allowed measurement of pro-ANP in serum
and plasma (with EDTA, heparin, or citrate). Briefly, patient
samples (1:40 dilution of 5 µl plasma in incubation buffer) or
standards were added in duplicate to antibody-coated tubes
(directed at pro-ANP peptide 73–90) and incubated for 30
min at room temperature. After five washings with 1 ml wash-
ing buffer, 200 µl tracer was added, containing acridinium
ester-labelled anti-pro-ANP antibody (directed at peptide 53–
72), followed by 30 min incubation at room temperature.
Tubes were washed three times with 1 ml washing buffer, and
detection was performed in a luminometer (1 s detection time
per sample). Relative light units of the chemiluminescence
assay were expressed in pmol/L pro-ANP, as calculated from
a calibration curve (4–1800 pmol/l) that was included in every
analytical run. The lower detection limit of the assay is 4.3
pmol/l and the functional sensitivity of the assay (interassay
coefficient of variation <20 %) is 11 pmol/L pro-ANP. The
97.5th percentile in 325 healthy individuals was 163.9 pmol/l
(median 45 pmol/l), with no difference between sexes [20].
PCT was measured using the LUMITest® PCT (BRAHMS
AG), following the manufacturer's instructions. CRP was
determined using en enzyme immunoassay (EMIT; Merck
Diagnostica, Zurich, Switzerland). A serum level greater than 5
mg/l was considered abnormally elevated. Serum IL-6 concen-
trations were measured using a commercially available quanti-
tative sandwich enzyme immunoassay (Pelikine Compact™;
CLB, Amsterdam, The Netherlands), with a limit of detection at
0.6 ng/l.
Statistical analysis
Data in the text are expressed as mean ± standard deviation.
Frequency comparison was done by χ2 test. Two-group com-
parisons were performed using the Mann–Whitney U-test. For
multigroup comparisons, Kruskal–Wallis one-way analysis of
variance was used with Dunn's post-test evaluation. Levels
that were nondetectable were assigned a value equal to the
lower limit of detection for the assay. All testing was two-tailed,
and P < 0.05 was considered statistically significant. Correla-
tion analyses were performed by using Spearman rank
correlation.
Results
Descriptive characteristics of the patients
The mean age of the 101 patients (55 men and 46 women)
included in the study was 57 ± 15 years (range 23–86 years)
and the mean APACHE II score on admission was 22 ± 8. The
median length of stay in the medical ICU was 4 days (range
0.2–60 days) and the mortality rate was 23%. More detailed
baseline characteristics of the study population are described
elsewhere [21]; however, to allow better understanding of the
study results, the principal diagnoses of patients are summa-
rized in Table 1 and the sites of infection in Table 2. Sepsis
was diagnosed in 58% of patients (on admission in 53
patients; five additional patients developed sepsis during their
stay in the ICU). The principal site of infection was the lung
(Table 2). In 38 (66%) of the 58 patients with infections, the
responsible micro-organism was identified and 14 patients
(24%) had bacteraemia. There was no difference in mortality
between patients with and those without infection. Of the 53
patients admitted with sepsis, severe sepsis, or septic shock,
13 (25%) died; 10 (21%) of the 48 patients without infection
on admission died.
Pro-atrial natriuretic peptide and severity of the 
disease
Figure 1a shows the distribution of pro-ANP values according
to severity of infection (i.e. SIRS, sepsis, severe sepsis and
septic shock) and serum PCT concentrations. Depending on
the clinical severity of the infection, pro-ANP values exhibited
a gradual increase from the group with SIRS to the group with
septic shock (P < 0.001). Similarly, circulating pro-ANP levels
showed a similar gradual increase when categorized based on
PCT levels (Fig. 1b).
Table 1
Clinical diagnoses of the patients
Diagnosis Details Number of patientsa
Respiratory Pneumonia (33), chronic obstructive pulmonary disease (14), acute asthma (3), bronchial 
carcinoma (3), pneumothorax (3), pharyngeal obstruction (2), toxic pulmonary oedema 
(2), Wegener's granulomatosis (1)
61
Cardiovascular Myocardial infarction (12), heart failure (11), pulmonary embolism (2) haemorrhagic 
shock (1)
26
Abdominal Gastrointestinal bleeding (7), abdominal infection (6), urinary tract infection (5), acute 
renal failure (3), hepatic coma (3)
24
Cerebral Ischaemic stroke (5), subarachnoid (4) or intracerebral (3) haemorrhage, seizures (3), 
suicidal intoxication with sedatives (5), cavernous sinus thrombosis (1)
21
Others Leukaemia (7), postoperative (6), diabetic coma (3), other infections (3) 19
aOne patient can have more than one diagnosis, and so the total exceeds the absolute number of patients (n = 101).Critical Care    February 2005  Vol 9 No 1    Morgenthaler et al.
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Post-test analysis revealed a significant difference (P < 0.001)
between patients without SIRS, SIRS, sepsis and severe sep-
sis as compared with patients with septic shock. There was no
significant difference between patients with severe sepsis and
those with septic shock. Accordingly, patients with PCT levels
greater than 10 ng/ml and greater than 1 ng/ml had signifi-
cantly higher pro-ANP levels than did patients with PCT levels
of 0.5–1 ng/ml and under 0.5 ng/ml (P < 0.001).
Pro-ANP levels correlated with serum IL-6 levels (r = 0.22; P
< 0.001), and with serum and urine osmolarity (r = 0.55 and r
= -0.43, respectively; P < 0.001), but not with serum sodium
(r = 0.03; not significant) and only weakly with urine sodium
concentrations (r = -0.17; P < 0.01).
Pro-atrial natriuretic peptide and outcomes in patients 
with sepsis, severe sepsis and septic shock
Figure 2 shows all pro-ANP values in survivors and nonsurvi-
vors with sepsis, severe sepsis or septic shock, measured dur-
ing their stay in the ICU. Thereby, patients were grouped by
clinical diagnosis of sepsis according to international guide-
lines (panels a and c) or by circulating PCT level in excess of
1 ng/ml (panels b and d). The median pro-ANP value in the
nonsurvivors was significantly greater than in the survivors,
independent of grouping used. This difference in pro-ANP val-
ues was clear on the first day of admission to the ICU (P <
0.001). In contrast, the difference between the survivors and
nonsurvivors on the first day of admission was not significant
for PCT (P = 0.38 and P = 0.05, respectively), CRP, or IL-6
(data not shown for CRP and IL-6). Similarly, in patients
without infections pro-ANP values were not higher in nonsur-
vivors than in survivors (all time points: 197.2 ± 361.5 pmol/l
versus 226.0 ± 183.4 pmol/l, P = 0.7; on admission: 221.5 ±
209.7 pmol/l versus 161.3 ± 132.1 pmol/l, P = 0.3).
To define an optimal decision threshold for pro-ANP values in
septic patients, we performed receiver operating characteris-
tic (ROC) plot analysis, including only data from patients with
sepsis, severe sepsis, or septic shock obtained within the first
48 hours after admission to the ICU. Sensitivity was calculated
among those patients who did not survive sepsis, and specifi-
city was assessed among those patients who were dis-
charged from the ICU. For comparison, the same ROC plot
analysis was performed with CRP, PCT, IL-6 and APACHE II
score. Table 3 shows the area under the ROC curve (AUC) for
all parameters, including the 95% confidence interval. The
AUC for pro-ANP was 0.88, which was significantly higher
than the AUCs for PCT and CRP, and similar to the AUC for
the APACHE II score (0.86). ROC curves are shown in Fig. 3.
Again, patients were grouped by clinical diagnosis of sepsis
according to international guidelines (panel a) or by circulating
PCT levels in excess of 1 ng/ml (panel b), yielding comparable
results.
The optimal threshold for pro-ANP was 530 pmol/l. At this cut-
off, the sensitivity for correct prediction of death in the ICU
was 86.7% and the specificity was 88.6%. Considering a
prevalence of 33% for death in the ICU as a result of sepsis,
the positive predictive value (PPV) of pro-ANP was 72.2%
with a negative predictive value (NPV) of 95.1%. None of
CRP, PCT, or IL-6 had similarly high values for sensitivity, spe-
cificity, PPV and NPV.
The APACHE II score was also predictive for prognosis but
yielded lower values as compared with pro-ANP. At an
APACHE II threshold of 30, the sensitivity was 73.3% and the
specificity was 95.6% (PPV = 84.6 %, NPV = 91.5 %). At a
cut-off of 25, which was recommended by the US Food and
Drug Administration for the use of Xigris®, sensitivity was
80.0%, specificity 75.6%, PPV 48.0% and NPV 91.4%.
Because PPV and NPV are dependent on the prevalence of
the disease, Table 4 shows the relative likelihood with the
prevalence independent likelihood ratio for different cut-offs.
Discussion
ANP and pro-ANP are markers for congestive heart failure [8-
10], but their pathophysiological and prognostic significance
Table 2
Site of infection and microbiology
Site of infection Details Number of patientsa
Lung Streptococcus pneumoniae (6), Pseudomonas aeruginosa (5), 
Haemophilus influenzae (3), Streptococcus pyogenes (3), 
Staphylococcus aureus (3), Klebsiella pneumoniae (2), Escherichia coli 
(2), Enterobacter spp. (2), Streptococcus salivarius (1), Legionella 
pneumophilia (1), unknown (16)
44
Urinary tract Escherichia coli (5), Pseudomonas aeruginosa (1) 6
Abdominal (gastrointestinal tract, liver, bile 
duct, and pancreas)
Clostridium difficile-associated colitis (1), unknown (4) 5
Others Meningococcal meningitis (1), sepsis with Torulopsis glabrata (1), malaria 
with Plasmodium falciparum (1)
3
aAn infection was diagnosed in 58% of the patients (on admission in 53 patients; five additional patients developed sepsis during their stay in the 
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in severe sepsis and septic shock is not yet understood. In the
present study we found a significant increase in mid-regional
pro-ANP in the plasma of sepsis patients as compared with
patients without sepsis and healthy individuals. This increase
was most marked in those patients with sepsis who did not
survive their disease. Importantly, on the first day of admission
to the ICU, pro-ANP, but not other markers of infection and
inflammation such as CRP and PCT, were significantly
increased in nonsurvivors as compared with survivors, sug-
gesting that pro-ANP levels represent a new and valuable
prognostic tool in patients with sepsis. At a threshold of 530
pmol/l, pro-ANP had a sensitivity of 86.7% for death in the ICU
with sepsis, with a specificity of 88.6%; these figures were not
reached by any of the other tested biomarkers.
As is generally recommended, we diagnosed sepsis, severe
sepsis and septic shock using well defined and widely
accepted clinical guidelines [25,26]. However, true gold
standards for the diagnosis of infections do not exist, and clin-
ical classification of critically ill patients is not 100% certain
despite the use of these guidelines, not only in sepsis trials but
also in routine bedside use [27,28]. An ideal sepsis marker
should permit early diagnosis, should provide information
about the course of disease, and should help to differentiate
bacterial from noninfectious and viral causes of systemic
inflammation. It was shown that PCT has some of these fea-
tures and is helpful in diagnosing septic conditions [29-31].
Therefore, we also classified pro-ANP levels according to cir-
culating PCT levels, which are not subject to the uncertainty
associated with clinical sepsis definitions. Importantly, the
prognostic value of pro-ANP was similar independent of the
classification system used, which suggests that our findings
are reproducible. Thus, pro-ANP is of prognostic value in crit-
ically ill septic patients, in contrast to PCT, which is predomi-
nantly a diagnostic parameter.
The first observations that ANP may play a role during endo-
toxic shock came from animal studies in which ANP was ele-
vated within 2–6 hours after lipopolysaccharide injection
[32,33]. Subsequent studies in critically ill humans showed an
association of ANP with various cardiac physiological param-
eters [34,35].
The use of different assays might be responsible for part of the
inconsistency in reported findings over recent years. Whereas
Berendes and coworkers [14] found no association of ANP
values with severity of the disease or mortality in critically ill
patients, Hartemink and coworkers [13] found a strong asso-
ciation of ANP levels with myocardial depression in septic
shock and with lethal outcome in 14 patients. A similar asso-
ciation of cardiac depression in septic shock was described
for NT-pro-ANP in 17 patients [12].
Unfortunately, a limitation of our study is that cardiac indices
were not routinely assessed by pulmonary artery catheter.
Figure 1
Pro-atrial natriuretic peptide (ANP) according to severity of disease  and circulating procalcitonin (PCT) levels Pro-atrial natriuretic peptide (ANP) according to severity of disease 
and circulating procalcitonin (PCT) levels. All patient data were 
grouped according to (a) the severity of the disease following con-
sensus criteria ('no SIRS',' SIRS', 'sepsis', 'severe sepsis' and 'septic 
shock') or (b) circulating PCT concentrations. Data from all time 
points (i.e. on admission, day 2, day of discharge and death) are dis-
played. Solid lines denote median values, boxes represent 25th to 
75th percentiles and whiskers indicate the range. ANOVA, analysis 
of variance.
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Figure 2
Pro-atrial natriuretic peptide (ANP) and procalcitonin (PCT) levels in surviving as compared with nonsurviving patients Pro-atrial natriuretic peptide (ANP) and procalcitonin (PCT) levels in surviving as compared with nonsurviving patients. Data from the patients on 
admission are shown. Patients were grouped (a, c) by clinical diagnosis of sepsis according to international guidelines or (b, d) by circulating PCT 
levels in excess of 1 ng/ml. Solid lines denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the range.
Table 3
Area under the curve of receiver operating characteristic plot analysis
Parameter AUC 95% CI P (versus pro-ANP)
Pro-ANP 0.88 0.77–0.95 -
APACHE II 0.86 0.74–0.93 0.79
IL-6 0.79 0.66–0.88 0.34
PCT 0.67 0.53–0.78 0.027
CRP 0.51 0.38–0.64 < 0.001
ANP, atrial natriuretic peptide; APACHE, Acute Physiology and Chronic Health Evaluation; AUC, area under the curve; CI, confidence interval; 
CRP, C-reactive protein; PCT, procalcitonin.
Table 4
Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and odds ratio at different cut-off levels of pro-ANP
Pro-ANP cut-off 
(pmol/l)
Sensitivity (95% CI) Specificity (95% CI) LR+ LR- Odds ratio (95% CI)
350 93% (68–99%) 77% (62–88%) 4.1 0.09 47.6 (5.5–408)
530 86% (59–98%) 88% (75–96%) 7.6 0.15 50.7 (8.7–293)
700 73% (44–92%) 93% (81–98%) 10.7 0.29 37.5 (7.3–193)
ANP, atrial natriuretic peptide; CI, confidence interval; LR-, negative likelihood ratio; LR+, positive likelihood ratio;
Clinical Sepsis PCT > 1 ng/ml
Survival Death
0
500
1000
1500
2000
m
i
d
r
e
g
i
o
n
a
l
p
r
o
A
N
P
(
p
m
o
l
/
l
) (a)
Survival Death
0
500
1000
1500
2000
m
i
d
r
e
g
i
o
n
a
l
p
r
o
A
N
P
(
p
m
o
l
/
l
) (b)
(c)
Survival Death
1
10
100
1000
P
C
T
(
n
g
/
m
l
)
(d)
Survival Death
1
10
100
1000
P
C
T
(
n
g
/
m
l
)Available online http://ccforum.com/content/9/1/R37
R43
Therefore, the precise mechanisms of pro-ANP release in
patients with sepsis remain unknown. Nevertheless, a cardiac
origin of natriuretic peptides makes an association with septic
cardiac dysfunction likely. In addition, apart from volume
overload, osmolarity rather than sodium concentration is asso-
ciated with pro-ANP release, as suggested by regression anal-
yses in our patients. Based on our findings and recent reports
in the literature [36], in critically ill patients increased levels of
natriuretic peptide are not specific for decompensated heart
failure. In this context, the increase in ANP levels in septic
shock may be potentiated by IL-6 elevation [15]. A recent
study in meningococcal sepsis provided conclusive evidence
that IL-6 is directly involved in myocardial depression [37].
Accordingly, in the present study IL-6 levels were correlated
with pro-ANP levels, albeit relatively weakly. IL-6 had lower
value in terms of outcome prediction than did mid-regional pro-
ANP, which may be due to differences in the half-life of the
molecules. The half-lives of both IL-6 and mature ANP are
short, and measurement of those markers in septic patients
does not allow a direct conclusion to be drawn regarding the
level of production. We recently developed a sandwich immu-
noassay for the detection of a mid-regional fraction of pro-ANP
in plasma [20]. This fragment has a much longer half-life in
plasma, and because it is produced in equimolar concentra-
tions to the mature hormone, it mirrors true production of ANP.
Furthermore, it is possible that mid-regional pro-ANP exerts a
physiological effect on its own, as is described for other frag-
ments of NT-pro-ANP [38] and fragments of other prohor-
mones, such as pro-adrenomedullin amino-terminal 20
peptide [39].
Measurement for ANP or fragments of NT-pro-ANP is poten-
tially influenced by other factors, such as sex, age and kidney
function, as is discussed elsewhere for brain-type natriuretic
peptides [40,41]. Indeed, we observed a significant correla-
tion of circulating pro-ANP levels with serum osmolarity and
creatinine. Measurements in nonseptic patients with kidney
failure revealed mostly normal pro-ANP values, and it is there-
fore possible that the observed elevation in pro-ANP and
creatinine in this study is a result of kidney failure related to
sepsis.
Sepsis is a complex syndrome, and the immunological and
biochemical situation may vary considerably between individ-
ual patients [3,4]. In the past almost all intervention trials failed
to show any benefit from therapy for sepsis, and sepsis inter-
vention has been termed the 'graveyard for pharmaceutical
companies' [7,42]. Reasons for this may be found in immuno-
logical heterogeneity and insufficient patient stratification in
those trials [5]. The need for markers that permit better strati-
fication of patients with different stages of sepsis is underlined
by the ongoing discussion concerning recombinant human
activated protein C (drotrecogin alpha; Xigris®) [42-45]. The
US Food and Drug Administration approved recombinant
human activated protein C only for those patients with an
APACHE II score in excess of 24, and thus only for those
patients with the greatest risk for dying [28,46,47]. The
APACHE II score – a complex algorithm – was not originally
developed for individual outcome prediction in sepsis patients
[48]. Despite its limitations, outcome predictors such as the
extensively evaluated APACHE II score are helpful in identify-
ing those septic patients who are at high risk for death and
who are more likely to benefit from intervention [6]. In the
present study the prognostic value of pro-ANP levels was
comparable to that of APACHE II score. Importantly, mid-
regional pro-ANP it is easier to determine than a physiological
score and mirrors distinct pathophysiological changes that
occur in sepsis.
Figure 3
Receiver operating characteristic plot analysis of different biomarkers  with respect to outcome prediction of sepsis Receiver operating characteristic plot analysis of different biomarkers 
with respect to outcome prediction of sepsis. Patient data on admis-
sion were grouped by (a) clinical diagnosis of sepsis according to 
international guidelines or by (b) circulating procalcitonin (PCT) lev-
els in excess of 1 ng/ml. Sensitivity was calculated in nonsurvivors, 
and specificity in survivors. APACHE, Acute Physiology and Chronic 
Health Evaluation; CRP, C-reactive protein; PCT, procalcitonin.
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Conclusion
In septic patients, we found that APACHE II score and mid-
regional pro-ANP level on admission to a medical ICU had sim-
ilar ability to predict outcome. The results of our study are
novel and of interest because they may help to improve strati-
fication of septic patients. Our findings are descriptive in
nature and warrant validation in future prospective studies,
including measurement of cardiac indices or evaluating
patients who have undergone surgery. If our findings are con-
firmed, then mid-regional pro-ANP might become a new and
useful additional prognostic marker for individual risk assess-
ment in sepsis, and may represent a helpful tool for patient
stratification in future intervention trials.
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